eligibility_summary
Eligible: ≥18, newly diagnosed de novo supratentorial GBM, CD70+ (≥5% at 1+), residual <3×3 cm, KPS>70, adequate marrow/renal/hepatic labs, neg pregnancy test, contraception required. Exclude: prior invasive cancer unless DF≥3y, infratentorial/extracranial or LM beyond skull, recurrent/multifocal, not cellular‑therapy candidate, immunosuppression/HIV, serious cardiac/infectious/resp/hepatic/autoimmune(on immunosupp.)/CTD, pregnant/lactating, other trial <30d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Ex vivo expanded autologous IL‑8 receptor (CXCR2)–modified CD70 CAR T cells (8R‑70CAR), type: gene‑engineered cellular immunotherapy (CAR‑T). Mechanism of action: The CAR specifically recognizes CD70 on glioblastoma cells to activate T‑cell cytotoxicity, co-expression of CXCR2 enhances trafficking and tumor infiltration by following IL‑8 (CXCL8) chemokine gradients abundant in the GBM microenvironment. Dosing: single IV infusion in a 3+3 dose‑escalation (10^6–10^8 cells/kg), one cohort adds cyclophosphamide/fludarabine lymphodepletion. Targets/pathways: CD70 on tumor cells, IL‑8/CXCR2 chemokine axis driving homing, effector CD4/CD8 T‑cell cytolysis and cytokine release against CD70+ GBM.